Profiles of drug substances, excipients, and related methodology最新文献_第5页

Piroxicam. 吡罗昔康。

Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 Epub Date: 2019-12-18 DOI: 10.1016/bs.podrm.2019.10.007

Gamal A E Mostafa, Abdullah S Al-Dosseri, Abdullah A Al-Badr

引用次数: 0

Emtricitabine. Emtricitabine。

Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 Epub Date: 2019-12-06 DOI: 10.1016/bs.podrm.2019.10.003

Abdulrahman A Al-Majed, Ahmed H H Bakheit, Bakr Mohammed Al-Qahtani, Hamad M Al-Kahtani, Ali S Abdelhameed

引用次数: 3

Erlotinib. 埃洛替尼。

Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 Epub Date: 2019-12-06 DOI: 10.1016/bs.podrm.2019.10.004

Ahmed A Abdelgalil, Hamad M Al-Kahtani, Fahad I Al-Jenoobi

{"title":"Erlotinib.","authors":"Ahmed A Abdelgalil, Hamad M Al-Kahtani, Fahad I Al-Jenoobi","doi":"10.1016/bs.podrm.2019.10.004","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.10.004","url":null,"abstract":"Erlotinib (OSI-774), marketed by Genentech as Tarceva®, is anticancer drug approved by US-FDA for the treatment of Non-Small Cell Lung Cancer (NSCLC) and Pancreatic Cancer. Erlotinib inhibited epidermal growth factor receptor (EGFR) that blocks tumor cell division, produces cell cycle arrest, and initiates programmed cell death in EGFR-overexpressing human tumor cells. This study presents a comprehensive profile of erlotinib, including detailed nomenclature, formula, elemental analysis, methods of preparation, physico-chemical characteristics, and methods of analysis (including spectroscopic, electrochemical, and chromatographic methods of analysis). Spectroscopic and spectrometric analyses include UV/vis spectroscopy, vibrational spectroscopy, nuclear magnetic resonance spectrometry ((1)H and (13)C NMR), and mass spectrometry. Chromatographic methods of analyses include thin layer chromatography, and high-performance liquid chromatography. Pharmacology of erlotinib including pharmacodynamics, mechanism of action, pharmacokinetics and drug-drug interactions were also presented. An appropriate table and figures were attached to each of the above mentioned sections along with total of 48 references.","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"45 ","pages":"93-117"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37731932","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Meloxicam. Meloxicam。

Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 Epub Date: 2019-12-12 DOI: 10.1016/bs.podrm.2019.10.006

Nasr Y Khalil, Khalid F Aldosari

{"title":"Meloxicam.","authors":"Nasr Y Khalil, Khalid F Aldosari","doi":"10.1016/bs.podrm.2019.10.006","DOIUrl":"https://doi.org/10.1016/bs.podrm.2019.10.006","url":null,"abstract":"Meloxicam, an oxicam derivative: 4-Hydroxy-2-methyl-N-(5-methyl-2-thiazolyl)-2H-1,2- benzothiazine-3-carboxamide 1,1-dioxide, is a nonsteroidal anti-inflammatory drug (NSAID). It is a selective inhibitor of cyclooxygenase-2 (COX-2). It is used in the management of rheumatoid arthritis, acute exacerbations of osteoarthritis, ankylosing spondylitis and juvenile idiopathic arthritis. It is given in a single oral dose of 7.5mg, increased if necessary to a maximum of 15mg daily (7.5mg in the elderly). It may also be given by rectal suppository in doses similar to those used orally. The reported side effects of meloxicam are similar to those of nonsteroidal anti-inflammatory drugs (NSAIDs), such as abdominal pain, anemia, and edema. There is also an increased risk of serious gastrointestinal (GI) adverse events, including ulceration and bleeding. This profile is prepared to discuss and explain physical characteristics, Proprietary and nonproprietary names of meloxicam. It also includes methods of preparation, thermal and spectral behavior, methods of analysis, pharmacokinetics, metabolism, excretion and pharmacology.","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"45 ","pages":"159-197"},"PeriodicalIF":0.0,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2019.10.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37732548","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 4

Index 指数

Profiles of drug substances, excipients, and related methodology Pub Date : 2020-01-01 DOI: 10.1016/s1871-5125(20)30010-8

引用次数: 0

Cocrystal Systems of Pharmaceutical Interest: 2012-2014. 医药领域的共晶系统:2012-2014。

Profiles of drug substances, excipients, and related methodology Pub Date : 2019-01-01 Epub Date: 2018-12-21 DOI: 10.1016/bs.podrm.2018.11.004

Harry G Brittain

引用次数: 6

Thiouracil: Comprehensive profile. 硫脲嘧啶:综合概况。

Profiles of drug substances, excipients, and related methodology Pub Date : 2019-01-01 Epub Date: 2019-01-10 DOI: 10.1016/bs.podrm.2018.11.006

Nasr Y Khalil, Haitham K AlRabiah, Mohammed S Almousa, Ahmed Bari, Hamad M Alkahtani

{"title":"Thiouracil: Comprehensive profile.","authors":"Nasr Y Khalil, Haitham K AlRabiah, Mohammed S Almousa, Ahmed Bari, Hamad M Alkahtani","doi":"10.1016/bs.podrm.2018.11.006","DOIUrl":"https://doi.org/10.1016/bs.podrm.2018.11.006","url":null,"abstract":"Thiouracil, 2-sulfanylidene-1H-pyrimidin-4-one, has been used as anti-thyroid, coronary vasodilator, and in congestive heart failure. It was found to cause agranulocytosis and it is suspected to be teratogenic and carcinogenic. Owing to its high frequency of adverse reactions, especially agranulocytosis, its use was abandoned in favor of other, less toxic drugs, such as propylthiouracil and methimazole. Thiouracil refers both to a specific molecule consisting of a sulfated uracil and a family of molecules based upon the structure. An important member of this family is propylthiouracil, which is a thiourea antithyroid drug that acts by blocking the production of thyroid hormones; it also inhibits the peripheral deiodination of thyroxine to tri-iodothyronine. This profile is prepared to discuss and explain physical and chemical properties, proprietary and nonproprietary names of thiouracil and propylthiouracil. It also includes uses and applications, methods of preparation, thermal and spectral behavior and methods of analysis. In addition, metabolism, excretion and pharmacology of propylthiouracil are also discussed.","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"44 ","pages":"293-331"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.006","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37191230","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 1

Paclitaxel. 紫杉醇。

Profiles of drug substances, excipients, and related methodology Pub Date : 2019-01-01 Epub Date: 2019-04-22 DOI: 10.1016/bs.podrm.2018.11.001

Fulwah Yahya Alqahtani, Fadilah Sfouq Aleanizy, Eram El Tahir, Hamad M Alkahtani, Bushra T AlQuadeib

引用次数: 0

Sorafenib. 索拉非尼。

Profiles of drug substances, excipients, and related methodology Pub Date : 2019-01-01 Epub Date: 2019-01-18 DOI: 10.1016/bs.podrm.2018.11.003

Ahmed A Abdelgalil, Hamad M Alkahtani, Fahad I Al-Jenoobi

{"title":"Sorafenib.","authors":"Ahmed A Abdelgalil, Hamad M Alkahtani, Fahad I Al-Jenoobi","doi":"10.1016/bs.podrm.2018.11.003","DOIUrl":"https://doi.org/10.1016/bs.podrm.2018.11.003","url":null,"abstract":"Sorafenib (BAY-43-9006), marketed by Bayer as Nexavar® (USA), is anticancer drug approved by US-FDA for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma. Sorafenib inhibited tumor growth and angiogenesis through targeting both the RAF/MEK/ERK pathway and receptor tyrosine kinases. This study presents a comprehensive profile of sorafenib, including detailed nomenclature, formula, elemental analysis, methods of preparation, physico-chemical characteristics, and methods of analysis (including spectroscopic, electrochemical, and chromatographic methods of analysis). Spectroscopic and spectrometric analyses include UV/vis spectroscopy, vibrational spectroscopy, nuclear magnetic resonance spectrometry ((1)H and (13)C NMR), and mass spectrometry. Chromatographic methods of analyses include thin layer chromatography and high-performance liquid chromatography. Only few stability indicating methods were found for quantification of sorafenib after exposing tablet dosage form to various stress conditions such as hydrolysis, oxidation, thermal stress, photo and UV light. However, none of these described methods were made to separate and quantify the degradation products. Pharmacology studies including pharmacodynamics, mechanism of action, pharmacokinetics and drug-drug interactions were also presented. An appropriate table and figures were attached to each of the above mentioned sections along with total of 55 references.","PeriodicalId":20802,"journal":{"name":"Profiles of drug substances, excipients, and related methodology","volume":"44 ","pages":"239-266"},"PeriodicalIF":0.0,"publicationDate":"2019-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/bs.podrm.2018.11.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37366647","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Contributors 贡献者

Profiles of drug substances, excipients, and related methodology Pub Date : 2019-01-01 DOI: 10.1016/s1871-5125(19)30011-1

引用次数: 0